HIV-1 Protease: Structural perspectives on drug resistance

Viruses

Volumn 1, Issue 3, 2009, Pages 1110-1136

  Weber, Irene T ^a   Agniswamy, Johnson ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Aspartic protease; Darunavir; Drug resistance; Molecular mechanism; Protease inhibitors

Indexed keywords

EID: 78349268413     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v1031110     Document Type: Review

References (89)

1. Weber, I.T.; Zhang, Y.; Tozser, J. HIV-1 Protease and AIDS Therapy. In Viral Proteases And Antiviral Protease Inhibitor Therapy; Lendeckel, U., Hooper, N., Eds., in press.
2. Palella, F.J., Jr.; Delaney, K.M.; Moorman, A.C.; Loveless, M.O.; Fuhrer, J.; Satten, G.A.; Aschman, D.J.; Holmberg, S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998, 338, 853-860.
3. Hammer, S.M.; Squires, K.E.; Hughes, M.D.; Grimes, J.M.; Demeter, L.M.; Currier, J.S.; Eron, J.J., Jr.; Feinberg, J.E.; Balfour, H.H., Jr.; Deyton, L.R.; Chodakewitz, J.A.; Fischl, M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 1997, 337, 725-733.
4. Sepkowitz, K.A. AIDS--the first 20 years. N. Eng. J. Med. 2001, 344, 1764-1772.
5. Ghosh, A.K.; Chapsal, B.D.; Weber, I.T.; Mitsuya, H. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc. Chem. Res. 2008, 41, 78-86.
6. Ghosh, A.K.; Leshchenko-Yashchuk, S.; Anderson, D.D.; Baldridge, A.; Noetzel, M.; Miller, H.B.; Tie, Y.; Wang, Y.F.; Koh, Y.; Weber, I.T.; Mitsuya, H. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. J. Med. Chem. 2009, 52, 3902-3914.
7. Mocroft, A.; Ruiz, L.; Reiss, P.; Ledergerber, B.; Katlama, C.; Lazzarin, A.; Goebel, F.D.; Phillips, A.N.; Clotet, B.; Lundgren, J.D. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003, 17, 1741-1751.
8. Leigh Brown, A.J.; Frost, S.D.; Mathews, W.C.; Dawson, K.; Hellmann, N.S.; Daar, E.S.; Richman, D.D.; Little, S. J. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J. Infect. Dis. 2003, 187, 683-686.
9. Richman, D.D.; Morton, S.C.; Wrin, T.; Hellmann, N.; Berry, S.; Shapiro, M.F.; Bozzette, S.A. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004, 18, 1393-1401.
10. Hurt, C.B.; McCoy, S.I.; Kuruc, J.; Nelson, J.A.; Kerkau, M.; Fiscus, S.; McGee, K.; Sebastian, J.; Leone, P.; Pilcher, C.; Hicks, C.; Eron, J. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir. Ther. 2009, 14, 673-678.
11. Grossman, Z.; Lorber, M.; Maayan, S.; Bar-Yacov, N.; Levy, I.; Averbuch, D.; Istomin, V.; Chowers, M.; Sthoeger, Z.; Ram, D.; Rudich, H.; Mileguir, F.; Pavel, R.; Almaliach, R.; Schlaeffer, F.; Kra-Oz, Z.; Mendelson, E.; Schapiro, J. M.; Riesenberg, K. Drug-resistant HIV infection among drug-naive patients in Israel. Clin. Infect. Dis. 2005, 40, 294-302.
12. Grant, R.M.; Hecht, F.M.; Warmerdam, M.; Liu, L.; Liegler, T.; Petropoulos, C.J.; Hellmann, N.S.; Chesney, M.; Busch, M.P.; Kahn, J.O. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288, 181-188.
13. Miller, V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J. Acquir. Immune. Defic. Syndr. 2001, 26 Suppl 1, S34-S50.
14. Shafer, R.W.; Schapiro, J.M. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 2008, 10, 67-84.
15. Hammer, S.M.; Saag, M.S.; Schechter, M.; Montaner, J.S.; Schooley, R.T.; Jacobsen, D.M.; Thompson, M.A.; Carpenter, C.C.; Fischl, M.A.; Gazzard, B.G.; Gatell, J.M.; Hirsch, M.S.; Katzenstein, D.A.; Richman, D.D.; Vella, S.; Yeni, P.G.; Volberding, P.A. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top. HIV. Med. 2006, 14, 827-843.
16. Kaplan, A.H.; Zack, J.A.; Knigge, M.; Paul, D.A.; Kempf, D.J.; Norbeck, D.W.; Swanstrom, R. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 1993, 67, 4050-4055.
17. Rose, J.R.; Babe, L. M.; Craik, C.S. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J. Virol. 1995, 69, 2751-2758.
18. Kohl, N.E.; Emini, E.A.; Schleif, W.A.; Davis, L.J.; Heimbach, J.C.; Dixon, R.A.; Scolnick, E.M.; Sigal, I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S. A 1988, 85, 4686-4690.
19. Peng, C.; Ho, B.K.; Chang, T.W.; Chang, N.T. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 1989, 63, 2550-2556.
20. Wlodawer, A.; Vondrasek, J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 249-284.
21. Noble, M.E.; Endicott, J.A.; Johnson, L.N. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303, 1800-1805.
22. Alymova, I.V.; Taylor, G.; Portner, A. Neuraminidase inhibitors as antiviral agents. Curr. Drug Targets. Infect. Disord. 2005, 5, 401-409.
23. Mittl, P.R.; Grutter, M.G. Opportunities for structure-based design of protease-directed drugs. Curr. Opin. Struct. Biol. 2006, 16, 769-775.
24. Ghosh, A.K. Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease. J. Med. Chem. 2009, 52, 2163-2176.
25. Rose, R.B.; Craik, C.S.; Stroud, R.M. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 1998, 37, 2607-2621.
26. Scott, W.R.; Schiffer, C.A. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure 2000, 8, 1259-1265.
27. Perryman, A.L.; Lin, J.H.; McCammon, J. A. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci. 2004, 13, 1108-1123.
28. Liu, F.; Kovalevsky, A.Y.; Louis, J.M.; Boross, P.I.; Wang, Y.F.; Harrison, R.W.; Weber, I.T. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. J. Mol. Biol. 2006, 358, 1191-1199.
29. Spinelli, S.; Liu, Q.Z.; Alzari, P.M.; Hirel, P.H.; Poljak, R.J. The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochimie 1991, 73, 1391-1396.
30. Tie, Y.; Boross, P.I.; Wang, Y.F.; Gaddis, L.; Hussain, A.K.; Leshchenko, S.; Ghosh, A.K.; Louis, J.M.; Harrison, R.W.; Weber, I.T. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J. Mol. Biol. 2004, 338, 341-352.
31. Gustchina, A.; Sansom, C.; Prevost, M.; Richelle, J.; Wodak, S.Y.; Wlodawer, A.; Weber, I.T. Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures. Protein Eng 1994, 7, 309-317.
32. Kovalevsky, A. Y.; Chumanevich, A. A.; Liu, F.; Louis, J.M.; Weber, I.T. Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry 2007, 46, 14854-14864.
33. Kumar, M.; Prashar, V.; Mahale, S.; Hosur, M.V. Observation of a tetrahedral reaction intermediate in the HIV-1 protease-substrate complex. Biochem. J. 2005, 389, 365-371.
34. Tie, Y.; Boross, P.I.; Wang, Y.F.; Gaddis, L.; Liu, F.; Chen, X.; Tozser, J.; Harrison, R.W.; Weber, I.T. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J. 2005, 272, 5265-5277.
35. Beck, Z.Q.; Morris, G.M.; Elder, J.H. Defining HIV-1 Protease Substrate Selectivity. Curr. Drug Targets. Infect. Disord. 2002, 2, 37-50.
36. Tozser, J. Comparative Studies on retroviral Proteases: Substrate Specificity. Viruses, submitted for publication, 2009.
37. Roberts, N.A.; Martin, J.A.; Kinchington, D.; Broadhurst, A.V.; Craig, J.C.; Duncan, I.B.; Galpin, S.A.; Handa, B.K.; Kay, J.; Krohn, A. Rational design of peptide-based HIV proteinase inhibitors. Science 1990, 248, 358-361.
38. Mehandru, S.; Markowitz, M. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. Expert. Opin. Investig. Drugs 2003, 12, 1821-1828.
39. Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J.F.; Boross, P.; Wang, Y.F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R.W.; Weber, I.T.; Ghosh, A.K.; Mitsuya, H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 2003, 47, 3123-3129.
40. Jacobsen, H.; Yasargil, K.; Winslow, D.L.; Craig, J.C.; Krohn, A.; Duncan, I.B.; Mous, J. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995, 206, 527-534.
41. Harrigan, P.R.; Hogg, R.S.; Dong, W.W.; Yip, B.; Wynhoven, B.; Woodward, J.; Brumme, C.J.; Brumme, Z.L.; Mo, T.; Alexander, C.S.; Montaner, J.S. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J. Infect. Dis. 2005, 191, 339-347.
42. Weiser, S.D.; Guzman, D.; Riley, E.D.; Clark, R.; Bangsberg, D.R. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV. Clin. Trials 2004, 5, 278-287.
43. Yasuda, J. M.; Miller, C.; Currier, J.S.; Forthal, D.N.; Kemper, C.A.; Beall, G.N.; Tilles, J.G.; Capparelli, E.V.; McCutchan, J.A.; Haubrich, R.H. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIVinfected patients. Antivir. Ther. 2004, 9, 753-761.
44. Paterson, D.L.; Swindells, S.; Mohr, J.; Brester, M.; Vergis, E.N.; Squier, C.; Wagener, M.M.; Singh, N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 2000, 133, 21-30.
45. Nolan, D.; Reiss, P.; Mallal, S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert. Opin. Drug Saf. 2005, 4, 201-218.
46. Wensing, A.M.; Boucher, C.A. Worldwide transmission of drug-resistant HIV. AIDS Rev. 2003, 5, 140-155.
47. Kuritzkes, D.R. Resistance to protease inhibitors. J. HIV. Ther. 2002, 7, 87-91.
48. Shafer, R.W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 2002, 15, 247-277.
49. Vergne, L.; Peeters, M.; Mpoudi-Ngole, E.; Bourgeois, A.; Liegeois, F.; Toure-Kane, C.; Mboup, S.; Mulanga-Kabeya, C.; Saman, E.; Jourdan, J.; Reynes, J.; Delaporte, E. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J. Clin. Microbiol. 2000, 38, 3919-3925.
50. Martinez-Cajas, J.L.; Wainberg, M.A. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. 2007, 76, 203-221.
51. Nijhuis, M.; van Maarseveen, N.M.; Lastere, S.; Schipper, P.; Coakley, E.; Glass, B.; Rovenska, M.; de Jong, D.; Chappey, C.; Goedegebuure, I.W.; Heilek-Snyder, G.; Dulude, D.; Cammack, N.; Brakier-Gingras, L.; Konvalinka, J.; Parkin, N.; Krausslich, H.G.; Brun-Vezinet, F.; Boucher, C.A. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS. Med. 2007, 4, e36.
52. Pereira-Vaz, J.; Duque, V.; Trindade, L.; Saraiva-da-Cunha, J.; Melico-Silvestre, A. Detection of the protease codon 35 amino acid insertion in sequences from treatment-naive HIV-1 subtype C infected individuals in the Central Region of Portugal. J. Clin. Virol. 2009, 46, 169-172.
53. Kozisek, M.; Saskova, K.G.; Rezacova, P.; Brynda, J.; van Maarseveen, N.M.; de Jong, D.; Boucher, C.A.; Kagan, R.M.; Nijhuis, M.; Konvalinka, J. Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region. J. Virol. 2008, 82, 5869-5878.
54. Tramuto, F.; Bonura, F.; Mancuso, S.; Romano, N.; Vitale, F. Detection of a new 3-base pair insertion mutation in the protease gene of human immunodeficiency virus type 1 during highly active antiretroviral therapy (HAART). AIDS Res. Hum. Retroviruses 2005, 21, 420-423.
55. Friend, J.; Parkin, N.; Liegler, T.; Martin, J.N.; Deeks, S.G. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004, 18, 1965-1966.
56. Velazquez-Campoy, A.; Muzammil, S.; Ohtaka, H.; Schon, A.; Vega, S.; Freire, E. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr. Drug Targets. Infect. Disord. 2003, 3, 311-328.
57. Kovalevsky, A.Y.; Liu, F.; Leshchenko, S.; Ghosh, A.K.; Louis, J.M.; Harrison, R.W.; Weber, I.T. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J. Mol. Biol. 2006, 363, 161-173.
58. Weber, I.T.; Kovalevsky, A.Y.; Harrison, R.W. Structures Of HIV Protease Guide Inhibitor Design To Overcome Drug Resistance. In Frontiers in Drug Design and Discovery: Structure-Based Drug Design in the 21st Century, 3rd ed.; Cladwell, G.W., Atta-ur-Rahman, Player, M.R., Choudhry, M.I., Eds.; Bentham Science Publishers Ltd., pp. 45-62
59. Tie, Y.; Kovalevsky, A.Y.; Boross, P.; Wang, Y.F.; Ghosh, A.K.; Tozser, J.; Harrison, R.W.; Weber, I.T. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins 2007, 67, 232-242.
60. Mahalingam, B.; Louis, J.M.; Reed, C.C.; Adomat, J.M.; Krouse, J.; Wang, Y.F.; Harrison, R.W.; Weber, I.T. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur. J. Biochem. 1999, 263, 238-245.
61. Liu, F.; Boross, P.I.; Wang, Y.F.; Tozser, J.; Louis, J.M.; Harrison, R.W.; Weber, I.T. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drugresistant mutations L24I, I50V, and G73S. J. Mol. Biol. 2005, 354, 789-800.
62. Hong, L.; Zhang, X.C.; Hartsuck, J.A.; Tang, J. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci. 2000, 9, 1898-1904.
63. Kozisek, M.; Bray, J.; Rezacova, P.; Saskova, K.; Brynda, J.; Pokorna, J.; Mammano, F.; Rulisek, L.; Konvalinka, J. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants. J. Mol. Biol. 2007, 374, 1005-1016.
64. Mahalingam, B.; Wang, Y.F.; Boross, P.I.; Tozser, J.; Louis, J.M.; Harrison, R.W.; Weber, I.T. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavirbinding site. Eur. J. Biochem. 2004, 271, 1516-1524.
65. Prabu-Jeyabalan, M.; Nalivaika, E.A.; King, N.M.; Schiffer, C.A. Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J. Virol. 2003, 77, 1306-1315.
66. Sayer, J. M.; Liu, F.; Ishima, R.; Weber, I.T.; Louis, J.M. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J. Biol. Chem. 2008, 283, 13459-13470.
67. Liu, F.; Kovalevsky, A.Y.; Tie, Y.; Ghosh, A.K.; Harrison, R.W.; Weber, I.T. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. J. Mol. Biol. 2008, 381, 102-115.
68. Kovalevsky, A.Y.; Tie, Y.; Liu, F.; Boross, P.I.; Wang, Y.F.; Leshchenko, S.; Ghosh, A.K.; Harrison, R.W.; Weber, I.T. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J. Med. Chem. 2006, 49, 1379-1387.
69. Mahalingam, B.; Louis, J.M.; Hung, J.; Harrison, R.W.; Weber, I.T. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 2001, 43, 455-464.
70. Ode, H.; Ota, M.; Neya, S.; Hata, M.; Sugiura, W.; Hoshino, T. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. J. Phys. Chem. B 2005, 109, 565-574.
71. Clemente, J.C.; Moose, R.E.; Hemrajani, R.; Whitford, L.R.; Govindasamy, L.; Reutzel, R.; McKenna, R.; Agbandje-McKenna, M.; Goodenow, M.M.; Dunn, B.M. Comparing the accumulation of active-and nonactive-site mutations in the HIV-1 protease. Biochemistry 2004, 43, 12141-12151.
72. Saskova, K.G.; Kozisek, M.; Rezacova, P.; Brynda, J.; Yashina, T.; Kagan, R.M.; Konvalinka, J. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir. J. Virol. 2009, 83, 8810-8818.
73. Logsdon, B.C.; Vickrey, J.F.; Martin, P.; Proteasa, G.; Koepke, J.I.; Terlecky, S.R.; Wawrzak, Z.; Winters, M.A.; Merigan, T.C.; Kovari, L.C. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J. Virol. 2004, 78, 3123-3132.
74. Martin, P.; Vickrey, J.F.; Proteasa, G.; Jimenez, Y.L.; Wawrzak, Z.; Winters, M.A.; Merigan, T.C.; Kovari, L. C. "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Structure 2005, 13, 1887-1895.
75. Prabu-Jeyabalan, M.; King, N.M.; Nalivaika, E.A.; Heilek-Snyder, G.; Cammack, N.; Schiffer, C.A. Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 2006, 50, 1518-1521.
76. Chellappan, S.; Kairys, V.; Fernandes, M.X.; Schiffer, C.; Gilson, M.K. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Proteins 2007, 68, 561-567.
77. Altman, M.D.; Ali, A.; Reddy, G.S.; Nalam, M.N.; Anjum, S.G.; Cao, H.; Chellappan, S.; Kairys, V.; Fernandes, M.X.; Gilson, M.K.; Schiffer, C.A.; Rana, T.M.; Tidor, B. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drugresistant variants. J. Am. Chem. Soc. 2008, 130, 6099-6113.
78. Bottcher, J.; Blum, A.; Dorr, S.; Heine, A.; Diederich, W. E.; Klebe, G. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors. ChemMedChem 2008, 3, 1337-1344.
79. Kozisek, M.; Cigler, P.; Lepsik, M.; Fanfrlik, J.; Rezacova, P.; Brynda, J.; Pokorna, J.; Plesek, J.; Gruner, B.; Grantz, S. K.; Vaclavikova, J.; Kral, V.; Konvalinka, J. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance. J. Med. Chem. 2008, 51, 4839-4843.
80. King, N.M.; Prabu-Jeyabalan, M.; Nalivaika, E.A.; Wigerinck, P.; de Bethune, M.P.; Schiffer, C.A. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 2004, 78, 12012-12021.
81. McKeage, K.; Perry, C.M.; Keam, S.J. Darunavir: a review of its use in the management of HIV infection in adults. Drugs 2009, 69, 477-503.
82. Katlama, C.; Esposito, R.; Gatell, J.M.; Goffard, J.C.; Grinsztejn, B.; Pozniak, A.; Rockstroh, J.; Stoehr, A.; Vetter, N.; Yeni, P.; Parys, W.; Vangeneugden, T. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007, 21, 395-402.
83. Haubrich, R.; Berger, D.; Chiliade, P.; Colson, A.; Conant, M.; Gallant, J.; Wilkin, T.; Nadler, J.; Pierone, G.; Saag, M.; van Baelen, B.; Lefebvre, E. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007, 21, F11-F18.
84. Kovalevsky, A.Y.; Ghosh, A.K.; Weber, I.T. Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir. J. Med. Chem. 2008, 51, 6599-6603.
85. Kovalevsky, A.Y.; Louis, J.M.; Aniana, A.; Ghosh, A.K.; Weber, I. T. Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease. J. Mol. Biol. 2008, 384, 178-192.
86. Ghosh, A.K.; Gemma, S.; Baldridge, A.; Wang, Y.F.; Kovalevsky, A.Y.; Koh, Y.; Weber, I.T.; Mitsuya, H. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. J. Med. Chem. 2008, 51, 6021-6033.
87. Ghosh, A.K.; Gemma, S.; Takayama, J.; Baldridge, A.; Leshchenko-Yashchuk, S.; Miller, H.B.; Wang, Y.F.; Kovalevsky, A.Y.; Koh, Y.; Weber, I.T.; Mitsuya, H. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies. Org. Biomol. Chem. 2008, 6, 3703-3713.
88. Amano, M.; Koh, Y.; Das, D.; Li, J.; Leschenko, S.; Wang, Y.F.; Boross, P.I.; Weber, I.T.; Ghosh, A.K.; Mitsuya, H. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 2007, 51, 2143-2155.
89. Ghosh, A.K.; Kulkarni, S.; Anderson, D.D.; Hong, L.; Baldridge, A.; Wang, Y.F.; Chumanevich, A.A.; Kovalevsky, A.Y.; Tojo, Y.; Masayuki, A.; Koh, Y.; Tang, J.; Weber, I.T.; Mitsuya, H. Design, Synthesis, Protein-Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance. J. Med. Chem., Epub 11 September 2009.